Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Renal Cell 24Kidney Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 5von Hippel-Lindau Disease 4Pheochromocytoma 2Paraganglioma 2Neoplasm Metastasis 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Hemangioblastoma 1Glioblastoma 1Endometrial Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Radiotherapy 9Cisplatin 9pembrolizumab 6Methods 6fludarabine 4Papillomavirus Vaccines 4Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 4Early Intervention, Educational 4Cyclophosphamide 4durvalumab 3aldesleukin 3Vaccines, Synthetic 3Vaccines 3Radiosurgery 3Radiation 3Platinum 3Palliative Care 3Paclitaxel 3Nivolumab 3Gemcitabine 3Carboplatin 3Brachytherapy 3Bleomycin 31,2-diaminocyclohexaneplatinum II citrate 3tremelimumab 2lenvatinib 2entinostat 2aflibercept 2Trastuzumab 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Vulvar Neoplasms × belzutifan × Clear all
NCT06677190 2025-11-05

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Dana-Farber Cancer Institute

Phase 2 Recruiting
32 enrolled
Gynecologic

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡